Accelerate Diagnostics Inc (NASDAQ:AXDX)’s share price shot up 2.2% during mid-day trading on Wednesday . The company traded as high as $23.53 and last traded at $22.76, with a volume of 594,993 shares traded. The stock had previously closed at $22.28.

A number of research firms have issued reports on AXDX. BTIG Research reissued a “buy” rating and set a $26.00 price target on shares of Accelerate Diagnostics in a research report on Sunday, May 15th. Piper Jaffray Cos. reissued an “overweight” rating and set a $25.00 price target on shares of Accelerate Diagnostics in a research report on Monday, May 16th. Zacks Investment Research lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 13th. Finally, JPMorgan Chase & Co. raised their price target on shares of Accelerate Diagnostics from $17.00 to $25.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 9th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $25.33.

The stock has a 50-day moving average price of $19.15 and a 200-day moving average price of $14.61. The firm’s market capitalization is $1.14 billion.

In other Accelerate Diagnostics news, Director Jack W. Schuler bought 4,270 shares of the business’s stock in a transaction on Friday, May 20th. The shares were bought at an average cost of $11.04 per share, with a total value of $47,140.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jack W. Schuler bought 88,316 shares of the business’s stock in a transaction on Friday, June 10th. The stock was acquired at an average cost of $14.69 per share, for a total transaction of $1,297,362.04. The disclosure for this purchase can be found here.

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.